Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: Insights for understanding the impact of rotavirus vaccination programs

Vaccine

Volumn 30, Issue SUPPL. 1, 2012, Pages

  Bányai, Krisztián ^a,b   László, Brigitta ^a,c   Duque, Jazmin ^d   Steele, A Duncan ^e   Nelson, E Anthony S ^f   Gentsch, Jon R ^d   Parashar, Umesh D ^d  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e PATH   (United States)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

G type; Molecular epidemiology; P type; Prevalence; Surveillance

Indexed keywords

ROTAVIRUS VACCINE;

AFRICA; ARTICLE; BIOSURVEILLANCE; GENOTYPE; GEOGRAPHICAL VARIATION (SPECIES); HUMAN; MORTALITY; PREVALENCE; PRIORITY JOURNAL; ROTAVIRUS; ROTAVIRUS INFECTION; SPECIES DIVERSITY; SYSTEMATIC REVIEW; TREND STUDY; VACCINATION; VIRUS STRAIN;

EID: 84859963822     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.111     Document Type: Article

References (43)

1. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9:565-572.
2. Parashar U.D., Burton A., Lanata C., Boschi-Pinto C., Shibuya K., Steele D., et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009, 200(Suppl 1):S9-S15.
3. Parashar U.D., Gibson C.J., Bresse J.S., Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006, 12:304-306.
4. Dennehy P.H. Rotavirus vaccines: an overview. Clin Microbiol Rev 2008, 21:198-208.
5. Widdowson M.A., Steele D., Vojdani J., Wecker J., Parashar U. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines. J Infect Dis 2009, 200(Suppl 1):S1-S8.
6. WHO Meeting of the immunization Strategic Advisory Group of Experts, April 2009-conclusions and recommendations. Wkly Epidemiol Rec 2009, 84:220-236.
7. Estes M.K., Kapikian A.Z. Rotaviruses. Fields Virology 2007, 1917-1974. Lippincott Williams & Wilkins/Wolters Kluwer, Philadelphia. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin (Eds.).
8. Gentsch J.R., Laird A.R., Bielfelt B., Griffin D.D., Banyai K., Ramachandran M., et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 2005, 192(Suppl 1):S146-S159.
9. Santos N., Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005, 15:29-56.
10. Martella V., Bányai K., Matthijnssens J., Buonavoglia C., Ciarlet M. Zoonotic aspects of rotaviruses. Vet Microbiol 2010, 140:246-255.
11. Matthijnssens J., Bilcke J., Ciarlet M., Martella V., Bányai K., Rahman M., et al. Rotavirus disease and vaccination: impact on genotype diversity. Future Microbiol 2009, 4:1303-1316.
12. Ward R.L., Clark H.F., Offit P.A. Influence of potential protective mechanisms on the development of live rotavirus vaccines. J Infect Dis 2010, 202(Suppl):S72-S79.
13. Bernstein D.I., Sack D.A., Rothstein E., Reisinger K., Smith V.E., O'Sullivan D., et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo controlled trial. Lancet 1999, 354:287-290.
14. Velázquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996, 335:1022-1028.
15. Hoshino Y., Kapikian A.Z. Rotavirus serotypes: classification and importance in epidemiology, immunity, and vaccine development. J Health Popul Nutr 2000, 18:5-14.
16. Bishop R.F., Barnes G.L., Cipriani E., Lund J.S. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983, 309:72-76.
17. Ward R.L., Bernstein D.I. Rotarix: a rotavirus vaccine for the world. Clin Infect Dis 2009, 48:222-228.
18. Clark H.F., Offit P.A., Ellis R.W., Eiden J.J., Krah D., Shaw A.R., et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996, 174(Suppl 1):S73-S80.
19. Clark H.F. A brief account of experiences leading to RotaTeq vaccine. Hum Vaccine 2008, 4:256-259.
20. Richardson V., Hernandez-Pichardo J., Quintanar-Solares M., Esparza-Aguilar M., Johnson B., Gomez-Altamirano C.M., et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010, 362:299-305.
21. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
22. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
23. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
24. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
25. Armah G.E., Sow S.O., Breiman R.F., Dallas M.J., Tapia M.D., Feikin D.R., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:606-614.
26. Linhares A.C., Velázquez F.R., Pérez-Schael I., Saez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371:1181-1189.
27. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
28. de Palma O., Cruz L., Ramos H., de Baires A., Villatoro N., Pastor D., et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. Br Med J 2010, 340:c2825.
29. Patel M., Pedreira C., De Oliveira L.H., Tate J., Orozco M., Mercado J., et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. J Am Med Assoc 2009, 301:2243-2251.
30. Gurgel R.G., Bohland A.K., Vieira S.C., Oliveira D.M., Fontes P.B., Barros V.F., et al. Incidence of rotavirus and all cause diarrhea in northeast Brazil following the introduction of a national vaccination program. Gastroenterology 2009, 137:1970-1975.
31. Clark H.F., Lawley D., Matthijnssens J., DiNubile M.J., Hodinka R.L. Sustained decline in cases of rotavirus gastroenteritis presenting to the Children's Hospital of Philadelphia in the new rotavirus vaccine era. Pediatr Infect Dis J 2010, 29:699-702.
32. Gentsch J.R., Parashar U.D., Glass R.I. Impact of rotavirus vaccination: the importance of monitoring strains. Future Microbiol 2009, 4:1231-1234.
33. Cascio A., Vizzi E., Alaimo C., Arista S. Rotavirus gastroenteritis in Italian children: can severity of symptoms be related to the infecting virus?. Clin Infect Dis 2001, 32:1126-1132.
34. Linhares A.C., Verstraeten T., Wolleswinkel-van den Bosch J., Clemens R., Breuer T. Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clin Infect Dis 2006, 43:312-314.
35. Bahl R., Ray P., Subodh S., Shambharkar B., Saxena M., Parashar U., et al. Incidence of severe rotavirus diarrhea in New Delhi, India, and G and P types of the infecting rotavirus strains. J Infect Dis 2005, 192(Suppl 1):S114-S119.
36. White L., García D., Boher Y., Blanco M., Perez M., Romer H., et al. Temporal distribution of human rotavirus serotypes 1-3, and 4 in Venezuelan children with gastroenteritis during 1979-1989. J Med Virol 1991, 34:79-84.
37. Kapikian A.Z. A rotavirus vaccine for prevention of severe diarrhoea of infants and young children: development, utilization and withdrawal. Novartis Found Symp 2001, 238:153-171. discussion 171-9.
38. Fu C., Wang M., Liang J., He T., Wang D., Xu J. Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study. Vaccine 2007, 25:8756-8761.
39. Grimwood K., Kirkwood C.D. Human rotavirus vaccines: too early for the strain to tell. Lancet 2008, 371:1144-1145.
40. Gentsch J.R., Woods P.A., Ramachandran M., Das B.K., Leite J.P., Alfieri A., et al. Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J Infect Dis 1996, 174(Suppl 1):S30-S36.
41. Iturriza-Gómara M., Dallman T., Bányai K., Böttiger B., Buesa J., Diedrich S., et al. Rotavirus surveillance in Europe, 2005-2008: web-enabled reporting and real-time analysis of genotyping and epidemiological data. J Infect Dis 2009, 200(Suppl 1):S215-S221.
42. Nelson E.A., Bresee J.S., Parashar U.D., Widdowson M.A., Glass R.I. Asian Rotavirus Surveillance Network. Rotavirus epidemiology: the Asian Rotavirus Surveillance Network. Vaccine 2008, 26:3192-3196.
43. Steele A.D., Ivanoff B. Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. Vaccine 2003, 21:361-367.